Pinto A L, Raymond K M, Bruck I, Antoniuk S A
Departmento de Pediatria, Universidade Federal do Paraná (UFPr), Curitiba, PR, Brasil.
Rev Saude Publica. 1998 Apr;32(2):148-52. doi: 10.1590/s0034-89101998000200007.
Biotinidase deficiency is an inheritable disorder of biotin metabolism. This disorder fulfills major criteria for consideration for newborn screening: the affected children do no show clinical signs in the newborn period; the disease is highly disabling; treatment is effective in preventing neurological sequelae if undertaken promptly.
Screening of 125,000 infants born in Paraná State was carried out to establish the prevalence of biotinidase deficiency. A simple colorimetric procedure was used to detect two infants with biotinidase deficiency (1:62,500), one of them with profound deficiency (1:125,000) and the other with partial deficiency (1:125,000) of the enzyme.
There were no known false-negative test results and 0.12% were false-positive, defined by further blood samples which were negative upon repeated testing. Sensitivity was 100% and specificity was 99.88%. Repeat blood samples could not be obtained in 63 (30%) suspected cases.
Newborn screening for biotinidase is useful in identifying affected children, is inexpensive and allows early intervention, which may prevent irreversible neurological damage.
生物素酶缺乏症是一种生物素代谢的遗传性疾病。这种疾病符合新生儿筛查的主要标准:患病儿童在新生儿期无临床症状;该疾病具有高度致残性;如果及时进行治疗,可有效预防神经后遗症。
对巴拉那州出生的125,000名婴儿进行筛查,以确定生物素酶缺乏症的患病率。采用一种简单的比色法检测出两名生物素酶缺乏症婴儿(患病率为1:62,500),其中一名为严重缺乏(患病率为1:125,000),另一名为该酶部分缺乏(患病率为1:125,000)。
未发现已知的假阴性检测结果,假阳性率为0.12%,通过重复检测呈阴性的进一步血样确定。灵敏度为100%,特异性为99.88%。63例(30%)疑似病例未能获取重复血样。
生物素酶新生儿筛查有助于识别患病儿童,成本低廉且能实现早期干预,从而预防不可逆的神经损伤。